Innovent Biologics and Daiichi Sankyo secure exclusive rights to commercialize Vanflyta® in China for FLT3-ITD positive AML, accelerating access to a targeted therapy
Executive summary: Innovent Biologics and Daiichi Sankyo entered an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in China for patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). The agreement accelerates access to a targeted therapy for a high-mortality leukemia subtype in China, combining Innovent’s local market reach with Daiichi Sankyo’s oncology development capabilities.
Who is involved: Innovent Biologics (01801.HK), Daiichi Sankyo (TSE: 4568), and regulatory authorities overseeing drug approvals in China.
Likely next: Submission for regulatory approval in China, followed by commercial launch planning and potential expansion to other indications or territories.
Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in China, targeting patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). The collaboration leverages Innovent’s commercial footprint in China and Daiichi Sankyo’s global oncology expertise to accelerate patient access to this targeted FLT3 inhibitor. Vanflyta® was approved by the FDA in 2023 for adult patients with FLT3-ITD+ AML in combination with chemotherapy. The agreement reflects growing interest in precision oncology partnerships between Western pharma and Chinese biotechs to address high-unmet-need hematologic malignancies in the world’s second-largest pharmaceutical market.
Timeline
- — Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China (PR Newswire)
Analysis — what this means
Likely next events
- Regulatory submission for Vanflyta® in China expected within 6 months (by Feb 2027)
- First commercial sales in China possible by Q3 2027 pending approval
- Potential expansion to relapsed/refractory FLT3-ITD+ AML cases post-initial launch
Sectors affected
- Oncology pharmaceuticals
- Acute myeloid leukemia (AML) therapeutics
- Biopharmaceutical commercialization in China
Regulatory implications
- China’s NMPA will review Vanflyta® under its innovative drug pathway, potentially prioritizing FLT3-targeted therapies
- Post-approval requirements may include real-world evidence collection on survival outcomes in Chinese patients
- Pricing and reimbursement negotiations with China’s NRDL likely to influence market access speed
Historical parallels
- Similar to the 2021 partnership between BeiGene and Pfizer for brukinsa in China, combining international oncology innovation with local commercialization
- Parallels the 2020 collaboration between Hutchmed and Eli Lilly for fruquintinib in colorectal cancer, which achieved NMPA approval in 2021
- Mirrors the 2019 AstraZeneca and Innovent deal for Imfinzi in lung cancer, which led to multiple approvals in China by 2022